Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
NCT ID NCT07763938
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This phase 1 trial is testing an experimental therapy called CD19/CD20 dual-target in vivo CAR-T for people with relapsed or refractory B-cell malignancies—blood cancers that have not responded to standard treatments. The approach uses a lentiviral product to engineer a patient's own immune cells to recognize and attack cancer cells that carry either CD19 or CD20 markers. The study aims to assess the safety, tolerability, and effectiveness of this treatment, measuring how well it shrinks tumors and how long responses last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19/CD20 dual-target in vivo CAR-T lentiviral product
- What this could lead to
- If successful, this could lead to a more effective and convenient treatment for blood cancers that have stopped responding to standard therapy, potentially offering a path to remission.
- What could go wrong
- This is an early-phase trial, so safety and efficacy are not yet established. CAR-T therapy carries risks of severe side effects, and the in vivo approach is experimental, so it may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY INDOLENT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental CAR T-Cell therapy targets tough lymphoma
- New cell therapy takes aim at Hard-to-Treat blood cancers
- Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
- New injection aims to control tough blood cancers in early trial
- New CAR T-Cell therapy aims to outperform current treatment for aggressive lymphoma
- New CAR-T therapy targets tough blood cancers in early trial